Apimeds Pharmaceuticals US, Inc
APUS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.54M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.54 Million |
|---|---|
| Enterprise Value | $18.84 Million |
| Earnings per Share | $-5.5 |
| Beta | 0.15 |
| Outstanding Shares | 1,632,818 |
Return
| Return on Equity | -54.65% |
|---|---|
| Return on Assets | -45.58% |
| Return on Invested Capital | -25.67% |
Valuation & Multiples
| P/E Ratio | -0.06 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | 0.05 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.69 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.77 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.61%▼ 0.28% |
|---|---|
| Total Invested | $383,653▼ 52.22% |
| Investors Holding | 7▲ 1.00% |
About Apimeds Pharmaceuticals US, Inc
2 employees
CEO: Erik C. Emerson
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment ...